Abstract 509P
Background
Novel immunotherapies (IO) show mixed responses, particular in context of brain metastases (BM). We therefore aimed to investigate the density of tumor-associated macrophages (TAM) in primary tumors (PT) and matched BM tissue samples.
Methods
We retrospectively identified patients who received resection of PT and BM between 01/1990 and 10/2022. Immunohistochemical staining and density quantification (positive cells/mm2) of TAMs (CD68+ & CD163+) was performed. Generated heatmaps were analyzed for heterogeneity as quantified by Shannon Entropy.
Results
We included 62 patients (61.3% male, 38.7% female) with matched samples: 46/62 non-small cell lung cancer, 8/62 breast cancer (BC), 8/62 renal cell carcinoma. Median CD163+ TAM density was 733 cells/mm2 (range 105-5110 cells/mm2) in BM and 407 cells/mm2 (range 52-1786 cells/mm2) in PT. Median CD68+ TAM density was 924 cells/mm2 (range 119-5521 cells/mm2) in BM and 744 cells/mm2 (range 99-2164 cells/mm2) in PT. CD163+ TAM density was significantly higher in BM compared to PT over all entities (p<.05). For CD68+ TAM, a significant difference was only observed in BC with higher density in BM than in PT (p=.016). Median difference in CD163+ TAM density between PT and BM was 163 cells/mm2 (range -1258-3602 cells/mm2) and 348 cells/mm2 (range -1390-4390 cells/mm2) in CD68+ TAM. No correlation between TAM density difference and clinical outcome (time to BM and OS from BM) was observed (p>.05). Median entropy for CD163+ TAM in BM was 15.8 (range 1.5-76.2) and 14.3 (range 0.5-45.2) in PT. Concerning CD68+ TAM, median entropy was 19.9 (range 1.8-88.7) in BM and 23.9 (range 1.9-54.9) in PT. A significant difference in entropy was only observed in BC as primary breast cancer CD68+ TAM showed lower entropy indices (p=.02). Median difference in entropy between PT and BM was 3.4 (range -34.8-41.3) in CD163+ TAM and 1.41 (range -34.4-39.9) in CD68+ TAM. No correlation of TAM entropy and clinical outcome (time to BM and OS from BM) was observed (p>.05).
Conclusions
TAM density is significantly higher in BM compared to PT. In BC, higher CD68+ TAM entropy was observed in BM, indicating higher herterogeneity. Further analyses with enlarged cohort and additional immune cell markers are ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association is gratefully acknowledged.
Disclosure
M. Mair: Other, Travel Support: Pierre Fabre. G. Heller: Other, Personal, Other: X4 Pharmaceuticals. J.N. Kather: Financial Interests, Personal, Invited Speaker: Fresenius, Eisai, MSD; Financial Interests, Personal, Advisory Board: Owkin, DoMore Diagnostics, Panakeia, London, UK. M. Preusser: Financial Interests, Personal, Advisory Board: Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman, CMC Contrast, GSK, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, Gan & Lee Pharmaceuticals; Financial Interests, Institutional, Research Grant, Clinical Trials and research: Boehringer Ingelheim, Bristol Meyers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dohme, Novocure, GSK, AbbVie; Financial Interests, Institutional, Coordinating PI: PharmaMar; Non-Financial Interests, Leadership Role, Brain Tumor Group Chair (current): EORTC; Non-Financial Interests, Leadership Role, EANO Past-President (current): EANO; Non-Financial Interests, Other, Member Multi-Site Guideline Advisory Group: ASCO. A.S. Berghoff: Financial Interests, Personal, Invited Speaker: Roche, Bristol Meyers Squibb, Merck, AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
14P - Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy
Presenter: MIGUEL GALINDO CAMPOS
Session: Poster session 09
15P - CBL E3 ubiquitin ligases are key inhibitory regulators in PD-1/LAG-3 co-signaling in human cancers, targeted through bispecific co-blockade
Presenter: Luisa Chocarro
Session: Poster session 09
16P - Terminally exhausted CD8+ T cells and increased immunosuppressive soluble factors in malignant ascites of patients with gastric cancer with peritoneal metastasis
Presenter: Hye Sook Han
Session: Poster session 09
17P - Continued expansion of long-lived effect CD8+ T cells associates with durable response post-PD-1 blockade
Presenter: Robert Watson
Session: Poster session 09
18P - Exposure of calreticulin is required for vitamin C immunomediated cancer surveillance
Presenter: Alessandro Cavaliere
Session: Poster session 09
19P - Preclinical and clinical significance of VEGF deprivation in ovarian cancer through a specific active immunotherapy
Presenter: Yanelys Morera
Session: Poster session 09
20P - The essential role of DNA repair in the pharmacological activities of AST-3424
Presenter: Fanying Meng
Session: Poster session 09
21P - Implications of KMT2C knockdown for DNA damage repair in breast cancer
Presenter: Philip Bredin
Session: Poster session 09
22P - Clinical significance of DNA damage response mutations in early stage NSCLC
Presenter: Haoran Zhang
Session: Poster session 09
23P - PMC-309: A highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive
Presenter: Cheon Ho Park
Session: Poster session 09